Insights
Recon takes an analytical look behind select developments in healthcare
Keep up with Recon Strategy Insights
Get an email each time we publish a new article
Search
- By Marc Herant
What’s your blood type?
The first report of a genome wide association study of Covid-19 severity on approximately 4000 patients and controls conducted in Spain and Italy identifies a locus on the 3rd…
- By Sophie Ranen and Nikhil Bhojwani
COVID-19 has accelerated the adoption of AI in healthcare. AI based tools and solutions can work quickly, be deployed at scale, and respond to the dynamic nature of the crisis. Use-cases span all face…
- By Marc Herant
Remdesivir works… but not enough to change the public health perspective
The eagerly awaited results of the remdesivir NIH trial are out, and it’s solid but not smashing, although this is a partial re…
- By Tory Wolff
Summary
NaviHealth is a leader in post-acute care management; since it manages but does not provide care, its impact is constrained by quality of available providers
By aligning with Optum clinical a…
- By Tory Wolff
Among Covid’s many repercussions, the recession shock will drive a sustained degradation of provider payer mix. I estimate that each 5% added to unemployment will incrementally reduce hospital[1] ope…
- By Tory Wolff
Health Affairs has put out another study – this one by Skopec and team (subscription access) - comparing post-acute care (PAC) among Medicare Advantage (MA) vs. traditional Medicare (FFS). And, once a…
- By Marc Herant
Hydroxychloroquine does not seem to help much in Covid-19 (with caveat)
There has been significant attention to the use of the antimalarial hydroxychloroquine in Covid-19, but data on impact has been …